Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γ
Ki Hoon Han, … , Christopher K. Glass, Oswald Quehenberger
Ki Hoon Han, … , Christopher K. Glass, Oswald Quehenberger
Published September 15, 2000
Citation Information: J Clin Invest. 2000;106(6):793-802. https://doi.org/10.1172/JCI10052.
View: Text | PDF
Article

Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator–activated receptor γ

  • Text
  • PDF
Abstract

The CCR2-mediated recruitment of monocytes into the vessel wall plays an important role in all stages of atherosclerosis. In recent studies, we have shown that lipoproteins can modulate CCR2 expression and have identified native LDL as a positive regulator. In contrast, oxidized LDL (OxLDL), which is mainly formed in the aortic intima, reduces CCR2 expression, promotes monocyte retention, and may cause pathological accumulation of monocytes in the vessel wall. We now provide evidence that OxLDL reduces monocyte CCR2 expression by activating intracellular signaling pathways that may involve peroxisome proliferator–activated receptor γ (PPARγ). Receptor-mediated uptake of the lipoprotein particle was required and allows for delivery of the exogenous ligand to the nuclear receptor. The suppression of CCR2 expression by OxLDL was mediated by lipid components of OxLDL, such as the oxidized linoleic acid metabolites 9-HODE and 13-HODE, known activators of PPARγ. Modified apoB had no such effect. Consistent with a participation of the PPARγ signaling pathway, BRL49653 reduced CCR2 expression in freshly isolated human monocytes ex vivo and in circulating mouse monocytes in vivo. These results implicate PPARγ in the inhibition of CCR2 gene expression by oxidized lipids, which may help retain monocytes at sites of inflammation, such as the atherosclerotic lesion.

Authors

Ki Hoon Han, Mi Kyung Chang, Agnes Boullier, Simone R. Green, Andrew Li, Christopher K. Glass, Oswald Quehenberger

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of THP-1–cell binding of DiO-labeled OxLDL lipids by various ...
Inhibition of THP-1–cell binding of DiO-labeled OxLDL lipids by various competitors. THP-1 cells were incubated for 1 hour at 4°C with microemulsions of DiO-lipids from OxLDL (0.5 μg of phospholipids per milliliter) in the absence (None) or presence of unlabeled lipids from OxLDL (Ox-lipid) at 20 μg phospholipids/mL, apoB from OxLDL (Ox-apoB) at 20 μg/mL, oxidized synthetic PAPC (OxPAPC) at 20 μg/mL phospholipids, and 10 μg/mL neutralizing mouse anti-human CD36 IgM, OKM5. The effect of the various competitors on the binding of DiO-OxLDL lipids was assessed by flow cytometry. All data are expressed as percentage of binding relative to that seen in the absence of competitor (100%) and represent the means ± SD of three independent experiments. The reductions in binding by the various competitors are statistically significant (P < 0.001, unpaired Student’s t test).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts